Infigratinib in Recurrent High-Grade Glioma Patients
Status:
Recruiting
Trial end date:
2023-07-29
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multicenter, Phase 0 trial that will enroll up to 20
participants with recurrent high-grade glioma with FGFR1 K656E or FGFR3 K650E mutation or
FGFR3-TACC3 translocation which are scheduled for resection. In the lead-in cohort, a total
of 20 participants will be enrolled into the proposed phase 0 clinical trial. Participants
will be administered infigratinib prior to surgical resection of their tumor.
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai
Collaborators:
Barrow Neurological Institute Ivy Brain Tumor Center QED Therapeutics